Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase

Oncology Reports

Volumn 17, Issue 1, 2007, Pages 153-159

  Nio, Yoshinori ^a   Iguchi, Chikage ^a   Kodama, Hiroshi ^a   Itakura, Masayuki ^b   Hashimoto, Koji ^b   Koike, Makoto ^b   Toga, Tomoko ^b   Maruyama, Riruke ^b   Fukushima, Masakazu ^c  

^a Kodama Breast Clinic   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Breast cancer; Cyclophosphamide; Dihydropyrimidine dehydrogenase; Thymidylate synthase; Uracil and tegafur (UFT)

Indexed keywords

1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; TEGAFUR; THYMIDYLATE SYNTHASE; URACIL;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYMOLOGY; FEMALE; HUMAN; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TEGAFUR; THYMIDYLATE SYNTHASE; URACIL;

EID: 35348838676     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.1.153     Document Type: Article

References (45)

1. Ohta K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 323-328, 1988.
2. Sulkes A, Benner S and Canetta R: Uracil-tegafur: An oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16: 3461-3475, 1998. (Pubitemid 28481645)
3. Van Cutsem E and Peeters M: Oral fluoropyrimidines in colorectal cancer. Semin Oncol 27 (suppl 10): 91-95, 2000.
4. Ho DH, Pazdur R, Covington W, et al: Comparison of 5- fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetra-hyfrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085-2088, 1998. (Pubitemid 28415651)
5. Gregory RK, Johnston SR, Smith IE and Miles D: UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. Oncology 14: 47-49, 2000.
6. Ogawa Y, Ishikawa T, Chung SH, et al: Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 23: 3453-3457, 2003. (Pubitemid 36975448)
7. Nio Y: Chemotherapy of pancreatic cancer - Adjuvant chemotherapy. Consensus Cancer Ther (in Japanese) 2: 28-31, 2003.
8. Iguchi C, Nio Y, Sato Y, et al: A case of recurrent ampullary carcinoma of the papilla of Vater in which a complete response was induced by combination therapy using radiotherapy and oral chemotherapy employing UFT and cyclophosphamide. Gan To Kagaku Ryoho (in Japanese) 26: 1641-1645, 1999.
9. Minari Y, Nio Y, Endo S, et al: A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy. Gan To Kagaku Ryoho (in Japanese) 27: 121-125, 2000.
10. Haga S, Shimizu T, Imamura H, et al: Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice. Anticancer Res 19: 1791-1796, 1999. (Pubitemid 29392739)
11. Endo M, Sinbori N, Sawada N, et al: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83: 127-134, 1999. (Pubitemid 29409488)
12. Van Triest B and Peters GJ: Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 57: 179-194, 1999. (Pubitemid 29481691)
13. Inada T, Ogata Y, Kubota T, et al: 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer. Anticancer Res 20: 2457-2462, 2000. (Pubitemid 30614451)
14. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
15. International Union Against Cancer. TNM classification of malignant tumours. 6th edition. John Wiley & Sons, Inc., 2002.
16. NCI-CTC version 2.0. Common toxicity criteria - Notice of modifications. (http://ctep.info.nih.gov/).
17. Prasad SR, Saini S, Sumner JE, et al: Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr 27: 380-384, 2003. (Pubitemid 36793188)
18. Kurosumi M, Akiyama F, Iwase T, et al: Commitee for Production of Histopathological Criteria, Japanese Breast Cancer Society. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 8: 1-2, 2001.
19. Spears SP, Gustavsson BG, Mitchell MS, et al: Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44: 4144-4150, 1984. (Pubitemid 14041649)
20. Naguib FNM, El-Kouni MH and Cha S: Enzyme of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985. (Pubitemid 16200794)
21. Takechi T, Uchida J, Fujioka A and Fukushima M: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11: 1041-1044, 1997. (Pubitemid 27439412)
22. Nio Y, Sato Y, Nagami H, et al: Neoadjuvant chemotherapy of gastric cancer with oral UFT (a mixture of uracil and futrafur) during the waiting period for surgery. Anticancer Res 18: 523-530, 1998. (Pubitemid 28174867)
23. Huang CL, Yokomise H, Kobayashi S, et al: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
24. Horiguchi J, Takei H, Koibuchi Y, et al: Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 86: 222-225, 2002. (Pubitemid 34185149)
25. Ichikawa W, Uetake H, Shirota Y, et al: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expression in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003. (Pubitemid 36182616)
26. Kakimoto M, Uetake H, Osanai T, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 223: 103-111, 2005. (Pubitemid 40693714)
27. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
28. Takenoue T, Nagawa H, Matsuda K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000. (Pubitemid 30215157)
29. Fujiwaki R, Hata K, Nakayama K, et al: Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis. Oncology 59: 152-157, 2000.
30. Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996. (Pubitemid 26020011)
31. Kuniyasu T, Nakamura T, Tabuchi Y and Kuroda Y: Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 83: 1300-1306, 1998. (Pubitemid 28460079)
32. Suda Y, Kuwashima Y, Tanaka Y, et al: Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines. Anticancer Res 19: 805-810, 1999. (Pubitemid 29168335)
33. Tsujitani S, Konishi I, Suzuki K, et al: Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin Cancer Res 19: 189-195, 2000. (Pubitemid 30490159)
34. Umehara A, Yoshimatsu K, Endo S, et al: The correlation between the intratumoral thymidylate synthase levels and clinicopathological factors in colorectal cancer patients. J Tokyo Wom Med Uni 70: 621-629, 2000.
35. Foekens JA, Romain S, Look MP, et al: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61: 1421-1425, 2001. (Pubitemid 34292567)
36. Choi J, Lim H, Nam DK, et al: Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 84: 186-192, 2001. (Pubitemid 32113443)
37. Ebuchi M, Sakamoto S, Kudo H, et al: Clinicopathological stages and piromidine nucleotide synthesis in human mammary carcinomas. Anticancer Res 15: 1481-1484, 1995.
38. Pestalozzi BC, Peterson HF, Gelber RD, et al: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997. (Pubitemid 27209522)
39. Komaki K, Kamamura Y, Ohmine Y, et al: Differences in thymidylate synthetase acitivity in involved nodes compared with primary tumor in breast cancer patients. Breast Cancer Res Treat 35: 157-162, 1995.
40. Nishimura R, Nagao K, Miyayama H, et al: Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 19: 5621-5626, 1999. (Pubitemid 30093339)
41. Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989. (Pubitemid 19172462)
42. Peters GJ, van der Wilt CL, van Groeningen CJ, et al: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12: 2035-2042, 1994. (Pubitemid 24356018)
43. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
44. Paradiso A, Simone G, Petroni S, et al: Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82: 560-567, 2000. (Pubitemid 30085191)
45. Aschele C, Debernardis D, Tunesi G, et al: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6: 4797-4802, 2000. (Pubitemid 32110422)